activin A receptor type 1
Last updated 15 Jul 2022
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
The ACVR1 gene provides instructions for making the activin receptor type-1 (ACVR1) protein, which is a member of a protein family called bone morphogenetic protein (BMP) type I receptors. BMP receptors span the cell membrane, so that one end of the protein remains inside the cell and the other end projects from the outer surface of the cell. This arrangement allows receptors to receive signals from outside the cell and transmit them inside to affect cell development and function.
Video picks for GenesVideo library
Normal function
The ACVR1 gene provides instructions for making the activin receptor type-1 (ACVR1) protein, which is a member of a protein family called bone morphogenetic protein (BMP) type I receptors. BMP receptors span the cell membrane, so that one end of the protein remains inside the cell and the other end projects from the outer surface of the cell. This arrangement allows receptors to receive signals from outside the cell and transmit them inside to affect cell development and function.
The ACVR1 protein is found in many tissues of the body including skeletal muscle and cartilage. It helps to control the growth and development of the bones and muscles, including the gradual replacement of cartilage by bone (ossification). This process occurs in normal skeletal maturation from birth to young adulthood.
The ACVR1 protein is normally turned on (activated) at appropriate times by molecules called ligands. Activation may occur when these ligands, such as BMPs or a protein called activin A, attach (bind) to the receptor or to other proteins with which it forms a complex. Another protein called FKBP12 can turn off (inhibit) ACVR1 by binding to the receptor and preventing inappropriate (leaky) activation in the absence of ligands.
Conditions referring to this gene or chromosome
Other names
activin A receptor type I
activin A receptor, type I
activin A receptor, type II-like kinase 2
activin A type I receptor
activin A type I receptor precursor
ActR-IA protein, human
ACTRI
ACVR1_HUMAN
ACVR1A
ACVRLK2
ALK2
hydroxyalkyl-protein kinase
SKR1
Patient picks for Genes

Diabetes
MHRA approves teplizumab to delay progression of type 1 diabetes
Teplizumab (Tzield) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to help delay the onset of Stage 3 type 1 diabetes (T1D). Read on to see what this means if you are prescribed teplizumab and what it does for you.
by Lawrence Higgins

Diabetes
Slowdown in type 2 diabetes cases
Some countries have seen a fall in new cases of type 2 diabetes according to a new review of the current evidence.
by Milly Evans

Diabetes
Can diet drinks cause type 2 diabetes?
We're all used to the headlines about the 'global epidemic' of type 2 diabetes. We should all know that completely unlike type 1 diabetes, getting type 2 diabetes is largely about lifestyle.
by Dr Sarah Jarvis

Diabetes
Continuous glucose monitoring in type 1 diabetes
Type 1 and type 2 diabetes are both potentially serious conditions which should always be taken seriously. They’re both diagnosed on the basis of high blood sugar. But in other respects they are very, very different. Type 2 is largely down to lifestyle – getting type 1 is absolutely nothing to do with whether you eat too much sugar, carry excess weight or don’t exercise enough. People with type 2 diabetes often never need insulin – those with type 1 need it from day one. Many people with type 2 diabetes never need treatment that carries a risk of disabling low blood sugar (hypoglycaemia) – people with type 1 live with this risk every day. As a result, many people with type 2 never need to check their blood sugar several times a day – for people with type 1, it’s a highly unwelcome occupational hazard.
by Dr Sarah Jarvis

Diabetes
Signs of type 2 diabetes found in children as young as eight
The early signs of type 2 diabetes are visible in children as young as eight years old, according to new research.
by Milly Evans

Diabetes
Changes in type 2 diabetes care - what it means for you
If you are living with type 2 diabetes your treatment may soon change to be tailored around you and your specific needs - which will help improve your long-term health. Read on to find out what the changes are and what they mean for you.
by Lawrence Higgins
Related patient information and medicines

Patient information leaflet
Nausea medicine
Ondansetron is also sometimes used to treat nausea and vomiting from gastroenteritis Gastroenteritis. Aprepitant Aprepitant to prevent sickness and fosaprepitant - these are newer medicines and work by blocking a chemical that acts on neurokinin receptors in the body to cause nausea. They are sometimes called neurokinin-1 receptor antagonists..

Patient information leaflet
Myasthenia gravis
Myasthenia gravis (MG) is a condition where muscles become easily tired and weak. It is due to a problem with how the nerves stimulate the muscles to tighten (contract). What causes myasthenia gravis. Myasthenia gravis is an autoimmune disease. This means that the immune system The immune system (which normally protects the body from infections).

Patient information leaflet
Diabetes and illness
It is very important to know how to cope with illness if you have diabetes or know or care for somebody with diabetes. Further information on managing diabetes during a period of illness is available on the Diabetes UK website (see Further Reading below for the link). There is also further information in the following sections on Type 1 diabetes.

Patient information leaflet
Diabetic kidney disease
Diabetic kidney disease is a complication that occurs in some people with diabetes. Diabetic kidney disease (diabetic nephropathy) is a complication that occurs in some people with diabetes. Diabetic kidney disease is one of the causes of chronic kidney disease Chronic kidney disease , a long-term condition where the kidneys do not work as well as.

Patient information leaflet
Insulin
Insulin is a hormone made naturally in the body by the pancreas. For more information on insulin, go to [https://patient.info/health/type-1-diabetes/insulins](https://patient.info/health/type-1-diabetes/insulins) Insulin is a hormone that is made by cells called beta cells. There are two different types of diabetes: Type 1 diabetes Type 1 diabetes.

Patient information leaflet
Mastocytosis and mast cell disorders
A mast cell is a type of white blood cell. There are several forms of mastocytosis. In one, there are too many mast cells in the body: in another the number of mast cells is normal but they are too active. What are mast cells. Mast cells are a type of white blood cell - together, our white blood cells play a major role in our immune system,.
Further reading and references
- activin A receptor type 1; MedlinePlus, National Library of Medicine.
- Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors. 2004 Dec;22(4):233-41. doi: 10.1080/08977190412331279890.
- de Sousa Lopes SM, Roelen BA, Monteiro RM, Emmens R, Lin HY, Li E, Lawson KA, Mummery CL. BMP signaling mediated by ALK2 in the visceral endoderm is necessary for the generation of primordial germ cells in the mouse embryo. Genes Dev. 2004 Aug 1;18(15):1838-49. doi: 10.1101/gad.294004.
- Fiori JL, Billings PC, de la Pena LS, Kaplan FS, Shore EM. Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva (FOP). J Bone Miner Res. 2006 Jun;21(6):902-9. doi: 10.1359/jbmr.060215.
- Groppe JC, Shore EM, Kaplan FS. Functional modeling of the ACVR1 (R206H) mutation in FOP. Clin Orthop Relat Res. 2007 Sep;462:87-92. doi: 10.1097/BLO.0b013e318126c049.
- Kaplan FS, Glaser DL, Pignolo RJ, Shore EM. A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton. Expert Opin Biol Ther. 2007 May;7(5):705-12. doi: 10.1517/14712598.7.5.705.
- Lin GT, Chang HW, Liu CS, Huang PJ, Wang HC, Cheng YM. De novo 617G-A nucleotide mutation in the ACVR1 gene in a Taiwanese patient with fibrodysplasia ossificans progressiva. J Hum Genet. 2006;51(12):1083-1086. doi: 10.1007/s10038-006-0069-2. Epub 2006 Nov 1.
- Nakajima M, Haga N, Takikawa K, Manabe N, Nishimura G, Ikegawa S. The ACVR1 617G>A mutation is also recurrent in three Japanese patients with fibrodysplasia ossificans progressiva. J Hum Genet. 2007;52(5):473-475. doi: 10.1007/s10038-007-0128-3. Epub 2007 Mar 10.
- Nikbakht H, Panditharatna E, Mikael LG, Li R, Gayden T, Osmond M, Ho CY, Kambhampati M, Hwang EI, Faury D, Siu A, Papillon-Cavanagh S, Bechet D, Ligon KL, Ellezam B, Ingram WJ, Stinson C, Moore AS, Warren KE, Karamchandani J, Packer RJ, Jabado N, Majewski J, Nazarian J. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nat Commun. 2016 Apr 6;7:11185. doi: 10.1038/ncomms11185.
- O'Connell MP, Billings PC, Fiori JL, Deirmengian G, Roach HI, Shore EM, Kaplan FS. HSPG modulation of BMP signaling in fibrodysplasia ossificans progressiva cells. J Cell Biochem. 2007 Dec 15;102(6):1493-503. doi: 10.1002/jcb.21370.
- Samad TA, Rebbapragada A, Bell E, Zhang Y, Sidis Y, Jeong SJ, Campagna JA, Perusini S, Fabrizio DA, Schneyer AL, Lin HY, Brivanlou AH, Attisano L, Woolf CJ. DRAGON, a bone morphogenetic protein co-receptor. J Biol Chem. 2005 Apr 8;280(14):14122-9. doi: 10.1074/jbc.M410034200. Epub 2005 Jan 25.
- Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, Connor JM, Delai P, Glaser DL, LeMerrer M, Morhart R, Rogers JG, Smith R, Triffitt JT, Urtizberea JA, Zasloff M, Brown MA, Kaplan FS. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006 May;38(5):525-7. doi: 10.1038/ng1783. Epub 2006 Apr 23.
- Valer JA, Sanchez-de-Diego C, Pimenta-Lopes C, Rosa JL, Ventura F. ACVR1 Function in Health and Disease. Cells. 2019 Oct 31;8(11):1366. doi: 10.3390/cells8111366.
- Zhang D, Schwarz EM, Rosier RN, Zuscik MJ, Puzas JE, O'Keefe RJ. ALK2 functions as a BMP type I receptor and induces Indian hedgehog in chondrocytes during skeletal development. J Bone Miner Res. 2003 Sep;18(9):1593-604. doi: 10.1359/jbmr.2003.18.9.1593.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

